Researchers from The University of Texas MD Anderson Cancer Center in Houston have found that pseudogenes alone and in combination with other clinical and molecular markers may help define prognostic subgroups in seven types of cancer. The findings also suggest new areas of research into the mechanistic roles pseudogenes play in cancer.